Innate Pharma Total Assets

Innate Pharma (IPHA) currently reports a total assets of $63M as of December 2025. That compares with $110M in the prior-year period — down 43.6% year over year. Use the charts on this page to explore Innate Pharma's total assets history and peer comparisons.

Innate Pharma's total assets decreased from $110M to $63M — a 43.6% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Innate Pharma reported $63M in total assets as of December 2025. That compares with $110M in the prior-year period — down 43.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total assets of $63M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Innate Pharma, and consider following IPHA for alerts when major investors trade the stock.

Innate Pharma is classified in the Healthcare sector. On total assets, it currently shows $63M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IPHA with unrelated industries.